Posted by Michael Wonder on 17 Oct 2024
Incyte announces Health Canada approval of Opzelura (ruxolitinib) cream for the treatment of atopic dermatitis and non-segmental vitiligo
16 October 2024 - First and only treatment approved by Health Canada for repigmentation of non-segmental vitiligo.
Incyte Biosciences Canada today announced that Health Canada has granted a Notice of Compliance for Opzelura (ruxolitinib (as ruxolitinib phosphate)) cream 1.5%, a non-steroidal topical Janus kinase inhibitor, for the topical treatment of mild to moderate atopic dermatitis in adult and paediatric patients 12 years of age and older whose disease is not adequately controlled with conventional topical prescription therapies (topical corticosteroids, topical calcineurin inhibitors) or when those therapies are not advisable.
